. 2016 Sep 19;7(44):71887–71903. doi: 10.18632/oncotarget.12114

Table 4. Risks for patients with breast cancer, depending on ER status in primary tumor and metastases.

				OS ^a		Trend test		OS ^b		Trend test
		Deaths, n		HR ^c	95% CI	P	χ²	HR ^c	95% CI	P	χ²
ER	Prim⁺/Met⁺	240	69	1.0 ^d	—	<0.001^*	20.81	1.0 ^d	—	0.004^*	13.61
	Prim⁻/Met⁺	59	27	1.28	0.81 to 2.01	0.287 ^**		1.18	0.75 to 1.86	0.470 ^**
	Prim⁺/Met⁻	106	45	1.74	1.19 to 2.56	0.005 ^**		1.66	1.13 to 2.44	<0.001 ^**
	Prim⁻/Met⁻	222	83	2.16	1.53 to 3.05	<0.001 ^**		1.80	1.28 to 2.53	<0.001 ^**
HR	Prim⁺/Met⁺	181	72	1.0 ^d	—	0.001 ^*	20.72	1.0 ^d	—	0.007 ^*	12.06
	Prim⁻/Met⁺	32	19	1.37	0.86 to 2.18	0.192 ^**		1.22	0.77 to 1.93	0.404 ^**
	Prim⁺/Met⁻	102	52	1.58	1.10 to 2.27	0.013 ^**		1.48	1.03 to 2.11	0.033 ^**
	Prim⁻/Met⁻	125	66	2.21	1.56 to 3.13	<0.001 ^**		1.78	1.27 to 2.50	<0.001 ^**

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HR, hazard ratio; OS, overall survival; Prim, receptor status of the primary lesion; Met, receptor status of the metastatic lesion; No., number of patients.

Adjusted for age and calendar year of primary breast cancer diagnosis, relapse diagnosis, progesterone receptor status, tumor stage, hormonal treatment, and chemotherapy.

From breast cancer diagnosis to death or censoring.

From breast cancer relapse to death or censoring.

HR positive: ER and/or PR positive; HR negative: ER and PR negative

Reference

Compare between 4 groups.

^**

Compare with Prim⁺/Met⁺ group.